Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basmisanil in children with Dup15q syndrome
NL-OMON53905Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of basmisanil in dup15q syndrome, sponsored by Roche. Primary endpoints: Vineland-3 Adaptive Behavior Composite, Incidence, nature, and severity of adverse events and serious adverse events and 9 more. Planned start Sep 2023; status: withdrawn.
02
Drugs
basmisanil
03
Conditions
dup15q syndrome
Beyond the preview
Go deeper on NL-OMON53905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53905.